open access

Vol 44, No 3 (2013)
Prace poglądowe / Reviews
Submitted: 2013-05-31
Published online: 2013-07-01
Get Citation

Mixed phenotype acute leukemia – how to diagnose, how to treat?

Benigna Konatkowska, Olga Zając-Spychała1, Jacek Wachowiak1
DOI: 10.1016/j.achaem.2013.07.014
·
Acta Haematol Pol 2013;44(3):215-221.
Affiliations
  1. Klinika Onkologii, Hematologii i Transplantologii Pediatrycznej UM w Poznaniu, Kierownik: prof. zw. dr hab. Jacek Wachowiak, Poznań, Polska

open access

Vol 44, No 3 (2013)
Prace poglądowe / Reviews
Submitted: 2013-05-31
Published online: 2013-07-01

Abstract

In 2009, the World Health Organization has published an updated classification of proliferative diseases, whereby biphenotypic acute leukemia and acute bilineal leukemia, which previously were two separate diseases, were replaced by a single name, mixed phenotype acute leukemia (MPAL). Incidence of MPAL is not exactly known and varies in different publications from 0.5 to 5% of all leukemias in children. In these patients genetic disorders are particularly important for both diagnosis and prognosis. However, due to the still unsatisfactory outcome, the main problem remains optimal therapeutic strategy of patients with MPAL. The majority of research points to better outcomes of MPAL treatment with usage of therapeutic programs for the treatment of acute lymphoblastic leukemia (ALL), although the results are worse than in patients with ALL. An attempt to standardize the therapeutic approach and further improve is the project iBFM AMBI2012.

Abstract

In 2009, the World Health Organization has published an updated classification of proliferative diseases, whereby biphenotypic acute leukemia and acute bilineal leukemia, which previously were two separate diseases, were replaced by a single name, mixed phenotype acute leukemia (MPAL). Incidence of MPAL is not exactly known and varies in different publications from 0.5 to 5% of all leukemias in children. In these patients genetic disorders are particularly important for both diagnosis and prognosis. However, due to the still unsatisfactory outcome, the main problem remains optimal therapeutic strategy of patients with MPAL. The majority of research points to better outcomes of MPAL treatment with usage of therapeutic programs for the treatment of acute lymphoblastic leukemia (ALL), although the results are worse than in patients with ALL. An attempt to standardize the therapeutic approach and further improve is the project iBFM AMBI2012.

Get Citation

Keywords

Biphenotypic acute leukemia; Mixed phenotype acute leukemia; Immunophenotype; Treatment

About this article
Title

Mixed phenotype acute leukemia – how to diagnose, how to treat?

Journal

Acta Haematologica Polonica

Issue

Vol 44, No 3 (2013)

Pages

215-221

Published online

2013-07-01

Page views

188

Article views/downloads

2067

DOI

10.1016/j.achaem.2013.07.014

Bibliographic record

Acta Haematol Pol 2013;44(3):215-221.

Keywords

Biphenotypic acute leukemia
Mixed phenotype acute leukemia
Immunophenotype
Treatment

Authors

Benigna Konatkowska
Olga Zając-Spychała
Jacek Wachowiak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl